Biocompatibles turns to new target for PC (phosphorylcholine) technology
This article was originally published in Clinica
UK company Biocompatibles has announced the first element of its strategic review of its business following the sale of its coronary stent business to Abbott earlier this year. The company plans to use its phosphorylcholine (PC) coating for PC Gel Systems - or polyionic complexes - a gel matrix containing PC. The programme, which has a range of applications including drug delivery, combines the company's expertise in polymer systems and drug-eluting devices, Biocompatibles says.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.